Sarepta Therapeutics, Inc.
SRPT
$16.66
$0.261.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 10.91% | -34.65% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.91% | -34.65% | |||
| Cost of Revenue | 95.86% | 3.56% | |||
| Gross Profit | -1,046.79% | -88.32% | |||
| SG&A Expenses | 39.62% | -33.36% | |||
| Depreciation & Amortization | 0.00% | 1.50% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 84.54% | -6.72% | |||
| Operating Income | -552.18% | -154.40% | |||
| Income Before Tax | -43.42% | -226.30% | |||
| Income Tax Expenses | 132.27% | 67.40% | |||
| Earnings from Continuing Operations | -57.18% | -191.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -57.18% | -191.39% | |||
| EBIT | -552.18% | -154.40% | |||
| EBITDA | -811.19% | -135.14% | |||
| EPS Basic | -50.35% | -189.36% | |||
| Normalized Basic EPS | -533.53% | -154.31% | |||
| EPS Diluted | -50.14% | -195.39% | |||
| Normalized Diluted EPS | -533.53% | -159.08% | |||
| Average Basic Shares Outstanding | 4.55% | 2.28% | |||
| Average Diluted Shares Outstanding | 4.55% | -5.99% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||